Asthma Severity in Women: The Influence of Training and Menopause (ATOM)
The ATOM Study: Asthma Severity in Women: The Influence of Training and Menopause
Introduction: Late-onset asthma in women is characterized by poor disease control and reduced quality of life despite intensive treatment with inhaled steroid and beta2-agonist. The condition is further worsened at menopause due to the loss of estrogen leading to increased asthma exacerbation frequency, increased airway inflammation and decreased lung function. Exercise training may increase disease control of asthma patients, but to what extent the same effect is seen in postmenopausal women with late-onset asthma is unknown. These asthma patients represent a phenotype that is characterized by low eosinophilic airway inflammation, severe symptoms, moderate obesity and poor response to conventional medicine. Thus, our hypothesis is that regular physical exercise is especially associated with an improvement in asthma control in this phenotype. The aim of this project is to test this hypothesis and to assess whether an improvement is associated with reduced local and systemic inflammation, change in heart function, lung function and/or body composition.
Study design: 40 postmenopausal women with late-onset asthma are recruited via the outpatient clinic at the Respiratory Department at Bispebjerg Hospital and through advertisement. The participants are randomized 1:1 into two groups. One group performs supervised exercise training (spinning) three times per week for 12 weeks while the other group is a control group. Before and after the intervention asthma control, local and systemic inflammation, heart function and body composition is measured.
Results: Analysis will be performed to detect changes within and between the groups before and after intervention. Primary outcome is change in ACQ (Asthma Control Questionnaire). Local and systemic inflammation is measured by changes in bronchial challenge to methacholine, sputum cell count and blood tests. Furthermore, secondary outcomes include change in heart function measured by stress-echocardiography and change in body composition measured by Dual-energy X-ray absorptiometry (DEXA).
Conclusion: There are to date no prospective studies that can support recommendations containing asthma rehabilitation with supervised regular physical activity for postmenopausal women. Thus, this study will provide novel understanding of the importance of physical activity in a chronic disease such as asthma.
調査の概要
詳細な説明
Overall study design
The study is a single-blinded randomized controlled intervention study. Forty postmenopausal women with late-onset asthma (>16 years at debut) are recruited from the asthma outpatient-clinic at Bispebjerg Hospital or other hospital/practitioner in the region and/or by advertisement. The participants are block-randomized into two groups of 20, where one group is control and the other undergoes a period of regular exercise training. The investigators will be blinded and will not know whether the subjects have trained or not.
Detailed study design
Participants allocated to the exercise training group undergo a training intervention consisting of 45 minutes of intermittent high intensity aerobic spinning training three times per week for 12 weeks. Participants allocated to the control group will continue usual care without training. No changes to current treatment will be made by the investigators on any of the groups.
The training will consist of short periods of high intensity intervals where subjects reach above 80% of maximal oxygen consumption. Spinning sessions will be fully supervised by trained instructors with a bachelor of sports and science or bachelor of medicine and conducted in the Department of Nutrition, Exercise and Sports, University of Copenhagen. Subjects will wear heart rate monitors to ensure adherence to the training protocol. Within two weeks, before and after the intervention, participants from both groups undergo 3 days of testing.
To ensure equal compliance with asthma medication both groups will receive daily electronic reminders. Once a week, all participants will be asked about their compliance to their medication.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Copenhagen、デンマーク、2400
- Respiratory research unit, Bispebjerg University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Late onset asthma (Debut ≥ 16 years of age)
- ACQ ≥ 1.25
- Daily treatment for asthma (GINA 2 and above)
- Age 45 - 75
- Postmenopausal defined as no menstruation for 6 months, Serum Follicle stimulating hormone >20 International Units per Liter and P-Estradiol nmol/L <0.09
- BMI 25 - 35
- Positive bronchial challenge to methacholine, mannitol or positive reversibility to beta2-agonist now or historically
- Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 months)
- Capable of exercising on a bike
Exclusion Criteria:
- Unable to speak and understand Danish or English.
- Current or former smokers (>6 months cessation) with >20 years of daily smoking with 20 cigarettes per day.
- Other respiratory disease of clinical significance
- Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (EF <40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (>155/100)
- Any disorder that is not stable and in the opinion of the investigator could affect the safety of the subject throughout the study
- Subjects, who by investigators determination, will not be able to adhere to study protocol
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Aerobic exercise intervention
Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
|
High Intensity Interval Training (HIIT)
|
|
介入なし：Control group
No intervention for 12 weeks
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Asthma control - Asthma Control Questionnaire (ACQ)
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in Asthma Control Questionnaire (ACQ) 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use)
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Heart Rate Variability
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in: - Heart rate variability |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart rhytm
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in: - Heart rhythm |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart Rate
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in: - electrocardiography |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Strain
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Strain |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Ejection fraction
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Ejection fraction |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Tricuspid annular plane systolic excursion
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Tricuspid annular plane systolic excursion |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Right ventricular function
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Right ventricular function |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Pulmonary pressure
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Pulmonary pressure |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Lung covered cor
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Measured by stress-echocardiography - Lung covered cor |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Blood pressure
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Blood pressure
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Cardiac output
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Cardiac output
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Stroke volume
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Stroke volume
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Heart function - Total peripheral resistance
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Total peripheral resistance
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Leukocytes + differential cell count count
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Leukocytes + differential cell count count |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Interleukin 6
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Interleukin 6 |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Interleukin 8
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Interleukin 8 |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Other interleukins |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Tumor Necrosis Factor alpha
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Tumor Necrosis Factor alpha |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - Total immunoglobulin E, Specific immunoglobulin E
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Systemic inflammation - high sensitivity c reactive protein
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - high sensitivity c reactive protein |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Local airway inflammation - Sputum cell count
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Sputum cell count |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Local airway inflammation - Fraction of exhaled nitric oxide
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Fraction of exhaled nitric oxide |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Local airway inflammation - Hyperreactivity to inhaled methacholine
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Hyperreactivity to inhaled methacholine |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Total body fat |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Lean body mass |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Muscle mass |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Body Composition
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Weight |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Microbiome
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in the microbiota in sputum, oral cavity and nasal cavity before and after the training intervention
|
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Compliance - Foster score
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Change in - Foster score Answers describe last weeks medicine use. Answers range form 0/7 - 7/7 with low values being worse. |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Other asthma related questionnaires - Nijmegen questionnaire
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Nijmegen questionnaire Values range from 0-64 and values below 20 are considered normal. |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Other asthma related questionnaires - Mini Asthma Quality of Life Questionnaire (miniAQLQ)
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Mini Asthma Quality of Life Questionnaire (miniAQLQ) 7-point Likert scale (7 = not impaired at all - 1 = severely impaired). |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
|
Other asthma related questionnaires - Hospital Anxiety and Depression Scale (HADS) 2 items with 7 questions regarding anxiety and depression. (0 = no sign of depression/anxiety, 21 = maximal signs of anxiety/depression)
時間枠：-21 to 0 days before intervention and 0 to 14 days post intervention
|
Changes in - Hospital Anxiety and Depression Scale (HADS) |
-21 to 0 days before intervention and 0 to 14 days post intervention
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Vibeke Backer, Physician、Respiratory Research Unit, Bispebjerg Hospital
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- ATOM (Radius Health, Inc.)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。